Literature DB >> 6839935

Acyclovir treatment in stromal herpetic keratitis.

R van Ganswijk, J A Oosterhuis, M Swart-van den Berg, J Versteeg.   

Abstract

Twenty-five patients with long standing deep stromal herpetic keratitis and iritis were treated with acyclovir (3%) ointment and corticosteroids. All patients healed in about two to four weeks, independent of the duration of the keratitis before acyclovir treatment and independent of the antiviral medication given previously. Recurrences could not be prevented by acyclovir treatment. No serious side effects of acyclovir were noted.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6839935     DOI: 10.1007/bf00140462

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  4 in total

1.  HERPES SIMPLEX TREATMENT WITH IDU AND CORTICOSTEROIDS.

Authors:  H E KAUFMAN; E L MARTOLA; C H DOHLMAN
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1963 Sep-Oct

2.  Acyclovir and trifluorothymidine in herpetic keratitis: a multicentre trial.

Authors:  C la Lau; J A Oosterhuis; J Versteeg; G van Rij; J G Renardel de Lavalette; A Craandijk; W P Lamers; W P Lamers
Journal:  Br J Ophthalmol       Date:  1982-08       Impact factor: 4.638

3.  Aciclovir and trifluorothymidine in herpetic keratitis. Preliminary report of a multicentered trial.

Authors:  C la Lau; J A Oosterhuis; J Versteeg; G van Rij; J G Renardel de Lavalette; A Craandijk; W R Lamers; T Mierlobensteyn
Journal:  Doc Ophthalmol       Date:  1981-03-20       Impact factor: 2.379

4.  Acyclovir and vidarabine in the treatment of ulcerative herpes simplex keratitis.

Authors:  D Pavan-Langston; J Lass; M Hettinger; I Udell
Journal:  Am J Ophthalmol       Date:  1981-12       Impact factor: 5.258

  4 in total
  1 in total

Review 1.  Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  D M Richards; A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-11       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.